Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24568178 | 0.79 | EPHX2 (0.38) | — | |
| SCHEMBL22655738 | 0.75 | ALDH1A1 (0.33) | ESR1CHRM1SLC6A4KCNH2SLC29A1 | |
| SCHEMBL15927308 | 0.71 | — | — | |
| SCHEMBL18155282 | 0.71 | — | — | |
| SCHEMBL6289961 | 0.71 | — | — | |
| SCHEMBL3896026 | 0.71 | — | — | |
| SCHEMBL18757311 | 0.71 | — | — | |
| SCHEMBL19014331 | 0.71 | CHRNB2 (0.43) | — | |
| SCHEMBL18704630 | 0.70 | CYP1A2 (0.44) | — | |
| SCHEMBL15808128 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183233-B2 | Stable pharmaceutical formulations | BAXTER INTERNATIONAL INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090286764-A1 | STABLE PHARMACEUTICAL FORMULATIONS | BAXTER INTERNATIONAL INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286764-A1 | STABLE PHARMACEUTICAL FORMULATIONS | GMPS, PRNP, PDE10A | ESR1 3301/4885CHRM1 3214/4885SLC6A4 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.